trending Market Intelligence /marketintelligence/en/news-insights/trending/nbi5ey4uqotz9hqa4tznjw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Homology Medicines increases share count for IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Homology Medicines increases share count for IPO

Homology Medicines Inc. raised the share count for its planned IPO on the Nasdaq Global Select Market to 10,350,000 common shares.

The new share count includes the overallotment option for the underwriters to buy up to an additional 1,350,000 shares.

The Bedford, Mass.-based genetic medicines company expects the offering price to be between $14.00 per share and $16.00 per share, and expects the shares to trade on the exchange under the symbol FIXX.

Previously, Homology planned to sell 7,667,050 common shares in the IPO, out of which underwriters had the option to buy 1,000,050 shares.

Homology also noted that certain of its existing stockholders, including entities affiliated with certain directors, have indicated an interest in buying about $50.0 million of common shares in the IPO.

Assuming an offering price of $15.00 per share, net proceeds from the offering are expected to be about $122.7 million, or $141.5 million if the underwriters fully exercise their overallotment option.

Merrill Lynch Pierce Fenner & Smith Inc., Cowen and Co. LLC, Evercore Group LLC and BTIG LLC are acting as underwriters for the offering.

Homology Medicines is focused on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.